Literature DB >> 11642248

Thalidomide for malignant melanoma.

G C Kudva, B T Collins, F R Dunphy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11642248     DOI： 10.1056/NEJM200110183451617

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  1 in total

1.  Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.

Authors:  Joseph I Clark; James Moon; Laura F Hutchins; Jeffrey A Sosman; W Martin Kast; Diane M Da Silva; P Y Liu; John A Thompson; Lawrence E Flaherty; Vernon K Sondak
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.